Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Garmin Ltd. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while Garmin Ltd. trades at $243.28 (market cap $46.89B). The key difference: Garmin Ltd. is the larger of the two by market cap, and Garmin Ltd. pays a 1.73% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GRMN | |
|---|---|---|
Market Cap | $39.89B | $46.89B |
Sector | Health | Technology |
52-Week High | $491.22 | $267.52 |
52-Week Low | $278.09 | $187.10 |
Enterprise Value | $38.15B | $44.35B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Garmin (GRMN) trades at $243.11, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with 2025 revenue of $7.25B and net income of $1.66B, maintaining robust profitability margins. Recent product launches in aviation and marine electronics highlight ongoing innovation. The stock is near its consensus price target of $282.67, indicating potential upside from current levels.
The outlook for GRMN remains positive driven by consistent earnings beats and dividend stability, though valuation multiples appear elevated. Key risks include competitive pressures in consumer electronics and reliance on discretionary spending. Analyst sentiment is cautious with 74% hold ratings, suggesting balanced risk-reward near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
